These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34152055)

  • 1. Simulated driving performance in healthy adults after night-time administration of 20 mg tasimelteon.
    Torres R; Fisher M; Birznieks G; Polymeropoulos C; Kay GG; Xiao C; Polymeropoulos MH
    J Sleep Res; 2022 Feb; 31(1):e13430. PubMed ID: 34152055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
    Lockley SW; Dressman MA; Licamele L; Xiao C; Fisher DM; Flynn-Evans EE; Hull JT; Torres R; Lavedan C; Polymeropoulos MH
    Lancet; 2015 Oct; 386(10005):1754-64. PubMed ID: 26466871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.
    Vermeeren A; Vets E; Vuurman EF; Van Oers AC; Jongen S; Laethem T; Heirman I; Bautmans A; Palcza J; Li X; Troyer MD; Wrishko R; McCrea J; Sun H
    Psychopharmacology (Berl); 2016 Sep; 233(18):3341-51. PubMed ID: 27424295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.
    Rajaratnam SM; Polymeropoulos MH; Fisher DM; Roth T; Scott C; Birznieks G; Klerman EB
    Lancet; 2009 Feb; 373(9662):482-91. PubMed ID: 19054552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tasimelteon: a melatonin receptor agonist for non-24-hour sleep-wake disorder.
    Johnsa JD; Neville MW
    Ann Pharmacother; 2014 Dec; 48(12):1636-41. PubMed ID: 25204464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
    Leger D; Quera-Salva MA; Vecchierini MF; Ogrizek P; Perry CA; Dressman MA
    Expert Opin Drug Saf; 2015; 14(11):1673-85. PubMed ID: 26393492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tasimelteon for treating non-24-h sleep-wake rhythm disorder.
    Nishimon S; Nishimon M; Nishino S
    Expert Opin Pharmacother; 2019 Jun; 20(9):1065-1073. PubMed ID: 30990759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers.
    Vermeeren A; Jongen S; Murphy P; Moline M; Filippov G; Pinner K; Perdomo C; Landry I; Majid O; Van Oers ACM; Van Leeuwen CJ; Ramaekers JG; Vuurman EFPM
    Sleep; 2019 Apr; 42(4):. PubMed ID: 30597112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.
    Vermeeren A; Sun H; Vuurman EF; Jongen S; Van Leeuwen CJ; Van Oers AC; Palcza J; Li X; Laethem T; Heirman I; Bautmans A; Troyer MD; Wrishko R; McCrea J
    Sleep; 2015 Nov; 38(11):1803-13. PubMed ID: 26039969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tasimelteon for the treatment of non-24-hour sleep-wake disorder.
    Neubauer DN
    Drugs Today (Barc); 2015 Jan; 51(1):29-35. PubMed ID: 25685859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and Treatment of Non-24-h Sleep-Wake Disorder in the Blind.
    Emens JS; Eastman CI
    Drugs; 2017 Apr; 77(6):637-650. PubMed ID: 28229310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tasimelteon (Hetlioz™): A New Melatonin Receptor Agonist for the Treatment of Non-24-Hour Sleep-Wake Disorder.
    Bonacci JM; Venci JV; Gandhi MA
    J Pharm Pract; 2015 Oct; 28(5):473-8. PubMed ID: 25092604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders.
    Hardeland R
    Curr Opin Investig Drugs; 2009 Jul; 10(7):691-701. PubMed ID: 19579175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator.
    Muehlan C; Brooks S; Vaillant C; Meinel M; Jacobs GE; Zuiker RG; Dingemanse J
    Clin Pharmacol Ther; 2022 Jun; 111(6):1334-1342. PubMed ID: 35426136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual effects of low-dose sublingual zolpidem on highway driving performance the morning after middle-of-the-night use.
    Vermeeren A; Vuurman EF; Leufkens TR; Van Leeuwen CJ; Van Oers AC; Laska E; Rico S; Steinberg F; Roth T
    Sleep; 2014 Mar; 37(3):489-96. PubMed ID: 24587571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the dual melatonin receptor agonist tasimelteon in subjects with hepatic or renal impairment.
    Torres R; Kramer WG; Baroldi P
    J Clin Pharmacol; 2015 May; 55(5):525-33. PubMed ID: 25450415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem.
    Leufkens TR; Lund JS; Vermeeren A
    J Sleep Res; 2009 Dec; 18(4):387-96. PubMed ID: 19552733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects.
    Mets MA; de Vries JM; de Senerpont Domis LM; Volkerts ER; Olivier B; Verster JC
    Sleep; 2011 Oct; 34(10):1327-34. PubMed ID: 21966064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals.
    Keating GM
    CNS Drugs; 2016 May; 30(5):461-8. PubMed ID: 27003694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a driving simulator for evaluating the residual effects of drugs on driving performance - sensitivity analysis using zopiclone as a positive control: Study Protocol Clinical Trial (SPIRIT Compliant).
    Iwata M; Iwamoto K; Kambe D; Tachibana N; Ando M; Ozaki N
    Medicine (Baltimore); 2020 Mar; 99(12):e19395. PubMed ID: 32195934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.